ZyVersa Therapeutics Inc. (ZVSA): PEG Multiple

Corporate company logo of ZyVersa (ZVSA)

ZyVersa Therapeutics (ZVSA) relies on a compact staff of elite researchers characterized by an academic culture and RSU-based incentives. The P/E growth potential metric reflects the asset's dynamics, where the 0.00 mark serves as a key value. Management is professionally developing therapies for renal inflammation, while the R&D strategy is based on organic growth and alliances with scientific institutes without external acquisitions.

ZyVersa (ZVSA): PEG Multiple from 04/28/2023 to 08/02/2025

Analytical breakdowns for ZyVersa Therapeutics (ZVSA)

- share price and consensus valuation forecast:
Price Performance Chart zyversa.com|ZVSA - Price Target Chart
- stock exchange capitalization data:
Market Capitalization ZyVersa|ZVSA - Enterprise Value
- balance sheet equity data:
Net Assets per Share ZyVersa Therapeutics|ZVSA - Book Capitalization|Capitalization to Book Value Ratio zyversa.com|ZVSA - Aggregate Company Assets
- debt obligations and liquidity statistics:
Debt to Equity Ratio ZyVersa Therapeutics|ZVSA - Long-Term Debt to Capital|Current Liabilities to Capital zyversa.com|ZVSA - Company Total Debt|Debts to Book Value ZyVersa|ZVSA - Company Long-Term Liabilities|Current Liabilities ZyVersa Therapeutics|Immediate Liquidity zyversa.com
- net income and valuation ratios data:
ZVSA - Net Income|Expected Profit ZyVersa Therapeutics|ZVSA - P/E Multiple|Projected Price to Earnings Ratio zyversa.com|ZVSA - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation ZyVersa|ZVSA - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters ZyVersa Therapeutics|ZVSA - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth zyversa.com|ZVSA - Net earnings per share growth this year|Expected earnings per share trend next year ZyVersa Therapeutics
- issuer revenue and sales details:
ZVSA - Company Sales|Company Projected Revenue Volume zyversa.com|ZVSA - P/S Multiple|Forward Price to Sales ZyVersa
Summary company analytics:ZVSA - ZyVersa Therapeutics Inc.
Manufactured products of ZyVersa

The efficiency of ZyVersa Therapeutics (ZVSA) pharmaceutical logistics in delivering kidney treatment drugs directly impacts capitalization rates and profit dynamics. The PEG ratio correlates the P/E ratio with earnings growth speed, allowing for the identification of an undervalued asset when values fall below one, which makes this chart a key tool for identifying high-growth companies or detecting the fading of growth drivers.

Who ZyVersa Therapeutics competes with

TVTX (Travere Therapeutics Inc) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Ardelyx Pharma ARDX|PEG Multiple ProKidney Pharma PROK|Akebia Therapeutics - PEG Multiple|Growth-Adjusted Market Cap to Net Income caratherapeutics.com TVRD|DMAC: PEG Multiple|Growth-Adjusted P/E Ratio UNCY|Price/Earnings to Growth Ratio Rockwell Medical, Inc.|Growth-Adjusted P/E Ratio CVKD (Cadrenal Therapeutics Inc)|PEG Multiple CDT|CALT - Price to Earnings Adjusted for Growth Rate|Renalytix PLC - Price/Earnings to Growth Multiple